about
A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patientsExpression and functional role of orphan receptor GPR158 in prostate cancer growth and progressionBeta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer.A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer.A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer.Automated analysis of co-localized protein expression in histologic sections of prostate cancer.Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cellsThe epothilones: new therapeutic agents for castration-resistant prostate cancer.Blood-based gene expression profiling in castrate-resistant prostate cancer.Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancerA Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumorsSafety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC).Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype.A pilot randomised controlled trial of a periodised resistance training and protein supplementation intervention in prostate cancer survivors on androgen deprivation therapy.3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound image fusion.Expression of androgen and estrogen related proteins in normal weight and obese prostate cancer patients.Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene.Salvage ablative therapy in prostate cancer: international multidisciplinary consensus on trial design.Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer?Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium.Prostate cancer: Age is nothing but a number.Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study.Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies.Show us a sign: the search for "game changing" prostate cancer biomarkers.Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells.Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors.A novel technique using three-dimensionally documented biopsy mapping allows precise re-visiting of prostate cancer foci with serial surveillance of cell cycle progression gene panel.Body image predicts quality of life in men with prostate cancer.Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and coping.Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years.Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial.Phase II Evaluations of Cilengitide in Asymptomatic Patients with Androgen-Independent Prostate Cancer: Scientific Rationale and Study DesignPhase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancerEffect of Monoamine oxidase A (MAOA) inhibitors on androgen-sensitive and castration-resistant prostate cancer cells
P50
Q28076622-3AECE4D9-7A01-4909-BEFE-D602BCF4C975Q28257270-2AA88EDD-5D29-4D00-9F5C-8D8EEB8899CBQ33280871-0FF7D83B-7056-4F60-AC60-FE583A35C575Q33292272-B967A0CB-13EA-4141-A49A-D2257718CE3CQ33462970-3775AAFC-5E41-4DF9-AE05-9B56E009B413Q33732080-035D4802-FF5D-4249-A88B-BF83B44A98B1Q33988851-6A406402-2BF8-4045-80B2-A9E105EF2924Q35584399-B72BD1CE-2278-4D4A-B039-E043A66F3234Q35772012-2FD707C1-F6FC-49CD-92F9-84352E674E7EQ36033412-6AD5877E-0089-457F-8E73-C7E69A90D077Q36660463-D4FA1A8A-AFE3-4174-AFF7-CC4B676A0947Q38615715-ACE42074-22EF-431F-B462-46D6E04E386EQ39293549-EE45EECD-88AF-4614-86D9-18E5FDCD2D54Q39429406-0968B7B3-1246-46F5-AC5F-15ABB2D6A1D5Q39661409-7A49BCD3-FAA0-4FCE-831D-FF1C76F85142Q39867400-A6C35A9C-1836-4123-A19C-89180D361FD0Q40269543-56CA6322-B529-45D8-98F2-DDB4544E2258Q40672689-C4364651-C346-4753-8149-F360A83BB436Q40919416-665D1486-FEF2-490A-B0A7-304ED89301C7Q41814914-879ABF37-AF0C-421B-81C4-A73DF00A39F1Q43414506-E57C07FB-E31E-4593-ABAD-A47848BBCC61Q43965995-D5124DA8-4B97-49D7-BACD-ABE3D42A3EDEQ44774280-98F5ACFA-F69B-4DAC-80B8-FCC92DE502C9Q46003525-C9B57FEC-A633-418C-9A3E-68F536ED01CAQ46140457-1777806D-D0B9-4DD4-8906-52BCDC3E71DBQ46153881-E157354B-B662-463F-929A-55AF9F7D4A64Q46167678-11C07087-5B76-45C7-B440-AC0AD40EC2B7Q46319926-89C51283-B074-450B-A156-003E4586ABDCQ46526772-8E1C480A-3088-4420-9B8D-300C975C9754Q46663012-6AB41838-FA7F-47F8-9649-A68A09F186C7Q46990082-F8A8C8D9-1075-4BE1-8836-C4B1617A3FE4Q57714784-D266D895-5DC9-4DA7-9073-941167AE257BQ89983831-DEDA3236-5E28-4B15-97A0-7FE89193243FQ91262157-14D65E51-6628-46C4-84E7-9E5D04E20EF6
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mitchell Gross
@ast
Mitchell Gross
@en
Mitchell Gross
@es
Mitchell Gross
@nl
Mitchell Gross
@sl
type
label
Mitchell Gross
@ast
Mitchell Gross
@en
Mitchell Gross
@es
Mitchell Gross
@nl
Mitchell Gross
@sl
prefLabel
Mitchell Gross
@ast
Mitchell Gross
@en
Mitchell Gross
@es
Mitchell Gross
@nl
Mitchell Gross
@sl
P106
P1153
56403871500
P31
P496
0000-0002-1691-921X